SRTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sensus Healthcare Inc (SRTS) is not a good buy for a beginner investor with a long-term strategy at this time. The company's financial performance is significantly weak, with sharp declines in revenue, net income, and EPS. Additionally, there are no strong positive catalysts, and the stock's technical indicators and trading trends do not suggest a compelling entry point. Analysts maintain a Buy rating, but recent price target adjustments reflect uncertainty. Given the lack of positive momentum and poor financials, holding off on this investment is recommended.
The MACD is slightly positive but contracting, indicating weak momentum. RSI is neutral at 47.994, and moving averages are converging, showing no clear trend. The stock is trading near its pivot point of 4.045, with resistance at 4.252 and support at 3.839. Overall, the technical indicators suggest a lack of strong directional movement.
Analyst Scott Henry initiated coverage with a Buy rating and a $7.50 price target, citing potential revenue growth from new reimbursement codes in 2026.
Significant financial underperformance in Q4 2025, with revenue down 62.20% YoY and net income down 304.85% YoY. No recent news or trading activity from insiders, hedge funds, or Congress. Stock trend analysis indicates a high probability of short-term declines.
In Q4 2025, revenue dropped to $4.94M (-62.20% YoY), net income fell to -$3.17M (-304.85% YoY), and EPS decreased to -0.19 (-311.11% YoY). Gross margin also declined to 38.41% (-29.38% YoY). Overall, the company's financials show significant deterioration.
Analysts maintain a Buy rating, but one analyst recently lowered the price target from $8 to $6 due to poor Q4 results. Another analyst has a higher price target of $7.50, expecting growth in 2026 due to new reimbursement codes.
